Crystal forms of valsartan disodium salt
Provided are crystal forms A, B, D, E, F, G and H of valsartan disodium salt and a preparation method therefor.
1. Crystalline form B of valsartan disodium salt, wherein, the crystalline form has the following properties:
by using a Cu-Ka radiation, its X-ray powder diffraction spectrum shows peaks at about 4.4±0.2 and 8.8±0.2, expressed in degree 2θ.
2. The crystalline form B of valsartan disodium salt according to claim 1 , which has a melting point of about 198±5° C.
3. Crystalline form D of valsartan disodium salt, wherein, the crystalline form has the following properties:
by using a Cu-Ka radiation, its X-ray powder diffraction spectrum shows peaks at about 4.4±0.2, 9.0±0.2, 14.9±0.2, 21.4±0.2, and 22.4±0.2, expressed in degrees 2θ.
4. The crystalline form D of valsartan disodium salt according to claim 3 , which has a melting point of about 207±5° C.
5. Crystalline form E of valsartan disodium salt, which is a dioxane solvate, wherein, the crystalline form has the following properties:
by using a Cu-Ka radiation, its X-ray powder diffraction spectrum shows peaks at about 6.3±0.2, 12.3±0.2, 14.7±0.2, 16.5±0.2, and 17.4±0.2, expressed in degrees 2θ.
6. The crystalline form E of valsartan disodium salt according to claim 5 , wherein, at a heating rate of 10° C./min, a differential scanning calorimetry thermogram of said crystalline form E of valsartan disodium salt shows an endothermic peak at around 127° C.
7. The crystalline form E of valsartan disodium salt according to claim 5 , wherein, at a heating rate of 10° C./min, a differential scanning calorimetry thermogram of said crystalline form E of valsartan disodium salt shows an endothermic peak at 107-127° C.
8. The crystalline form E of valsartan disodium salt according to claim 5 , wherein, at a heating rate of 10° C./min, there is a thermal weight loss of said crystalline form E of valsartan disodium salt of not less than 15% at 64-200° C.
9. The crystalline form E of valsartan disodium salt according to claim 5 , wherein, a ratio of valsartan disodium salt to dioxane in the crystalline form is 1:1.
10. Crystalline form F of valsartan disodium salt, which is an ethyl acetate solvate, wherein, the crystalline form has the following properties:
by using a Cu-Ka radiation, its X-ray powder diffraction spectrum shows peaks at about 6.2±0.2, 14.9±0.2, and 18.3±0.2, expressed in degrees 2θ.
11. The crystalline form F of valsartan disodium salt according to claim 10 , wherein, at a heating rate of 10° C./min, a differential scanning calorimetry thermogram of said crystalline form F of valsartan disodium salt shows an endothermic peak at around 116° C.
12. The crystalline form F of valsartan disodium salt according to claim 10 , wherein, at a heating rate of 10° C./min, a differential scanning calorimetry thermogram of said crystalline form F of valsartan disodium salt shows an endothermic peak at 104-117° C.
13. The crystalline form F of valsartan disodium salt according to claim 10 , wherein, at a heating rate of 10° C./min, there is a thermal weight loss of said crystalline form F of valsartan disodium salt of not less than 8.4% at 55-150° C.
14. The crystalline form F of valsartan disodium salt according to claim 10 , wherein, a ratio of valsartan disodium salt to ethyl acetate in the crystalline form is 1:0.5.
15. Crystalline form G of valsartan disodium salt, wherein, the crystalline form has the following properties:
by using a Cu-Ka radiation, its X-ray powder diffraction spectrum shows peaks at about 6.4±0.2, 8.3±0.2, 9.5±0.2, 17.3±0.2, and 19.4±0.2, expressed in degrees 2θ.
16. The crystalline form G of valsartan disodium salt according to claim 15 , wherein, at a heating rate of 10° C./min, degradation and melting signals in a differential scanning calorimetry curve overlap.
17. Crystalline form H of valsartan disodium salt, wherein, the crystalline form has the following properties:
by using a Cu-Ka radiation, its X-ray powder diffraction spectrum shows peaks at about 4.5±0.2, 8.7±0.2, and 9.0±0.2, expressed in degrees 2θ.
18. A pharmaceutical composition, comprising:
the crystalline form G of valsartan disodium salt according to claim 15 ; and
a pharmaceutically acceptable carrier.
19. A method for treating a disease or condition which is susceptible to treatment by blocking AT 1 receptor, comprising:
administering the crystalline form G of valsartan disodium salt according to claim 15 to a subject in need thereof, wherein the disease or condition comprises hypertension, congestive heart failure, acute renal failure, chronic renal failure, restenosis after percutaneous transluminal angioplasty, and restenosis after coronary artery bypass surgery; atherosclerosis, coronary heart disease, senile hypertension, and endothelial dysfunction with hypertension.
20. A pharmaceutical composition, comprising:
the crystalline form B of valsartan disodium salt according to claim 1 ; and
a pharmaceutically acceptable carrier.
21. A method for treating a disease or condition which is susceptible to treatment by blocking AT 1 receptor, comprising:
administering the crystalline form B of valsartan disodium salt according to claim 1 to a subject in need thereof,
wherein the disease or condition comprises hypertension, congestive heart failure, acute renal failure, chronic renal failure, restenosis after percutaneous transluminal angioplasty, and restenosis after coronary artery bypass surgery; atherosclerosis, coronary heart disease, senile hypertension, and endothelial dysfunction with hypertension.
22. A pharmaceutical composition, comprising:
the crystalline form D of valsartan disodium salt according to claim 3 ; and
a pharmaceutically acceptable carrier.
23. A method for treating a disease or condition which is susceptible to treatment by blocking AT 1 receptor, comprising:
administering the crystalline form D of valsartan disodium salt according to claim 6 to a subject in need thereof,
wherein the disease or condition comprises hypertension, congestive heart failure, acute renal failure, chronic renal failure, restenosis after percutaneous transluminal angioplasty, and restenosis after coronary artery bypass surgery; atherosclerosis, coronary heart disease, senile hypertension, and endothelial dysfunction with hypertension.
24. A pharmaceutical composition, comprising:
the crystalline form E of valsartan disodium salt according to claim 5 ; and
a pharmaceutically acceptable carrier.
25. A method for treating a disease or condition which is susceptible to treatment by blocking AT 1 receptor, comprising:
administering the crystalline form E of valsartan disodium salt according to claim 5 to a subject in need thereof,
wherein the disease or condition comprises hypertension, congestive heart failure, acute renal failure, chronic renal failure, restenosis after percutaneous transluminal angioplasty, and restenosis after coronary artery bypass surgery; atherosclerosis, coronary heart disease, senile hypertension, and endothelial dysfunction with hypertension.
26. A pharmaceutical composition, comprising:
the crystalline form F of valsartan disodium salt according to claim 10 ; and
a pharmaceutically acceptable carrier.
27. A method for treating a disease or condition which is susceptible to treatment by blocking AT 1 receptor, comprising:
administering the crystalline form F of valsartan disodium salt according to claim 10 to a subject in need thereof,
wherein the disease or condition comprises hypertension, congestive heart failure, acute renal failure, chronic renal failure, restenosis after percutaneous transluminal angioplasty, and restenosis after coronary artery bypass surgery; atherosclerosis, coronary heart disease, senile hypertension, and endothelial dysfunction with hypertension.
28. A pharmaceutical composition, comprising:
the crystalline form H of valsartan disodium salt according to claim 17 ; and
a pharmaceutically acceptable carrier.
29. A method for treating a disease or condition which is susceptible to treatment by blocking AT 1 receptor, comprising:
administering the crystalline form H of valsartan disodium salt according to claim 17 to a subject in need thereof,
wherein the disease or condition comprises hypertension, congestive heart failure, acute renal failure, chronic renal failure, restenosis after percutaneous transluminal angioplasty, and restenosis after coronary artery bypass surgery; atherosclerosis, coronary heart disease, senile hypertension, and endothelial dysfunction with hypertension.